Antifibrotic effect after low-dose imatinib mesylate treatment in patients with nephrogenic systemic fibrosis: An open-label non-randomized, uncontrolled clinical trial

Journal of the European Academy of Dermatology and Venereology

Volumn 27, Issue 6, 2013, Pages 779-784

  Elmholdt, T R ^a,b   Buus, N H ^b   Ramsing, M ^b   Olesen, A B ^b  

^a AARHUS UNIVERSITY   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB;

ADULT; ARTICLE; BACTERIAL INFECTION; CASE REPORT; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ENTEROCOLITIS; FEMALE; FEVER; GONIOMETER; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; JOINT MOBILITY; LOW DRUG DOSE; MALE; NEPHROGENIC SYSTEMIC FIBROSIS; PAIN; PRIORITY JOURNAL; QUALITY OF LIFE; RODNAN SKIN SCORE; SCORING SYSTEM; SKIN BIOPSY; SKIN FIBROSIS; THROMBOCYTOPENIA; URTICARIA; VOMITING;

ADULT; BENZAMIDES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEPHROGENIC FIBROSING DERMOPATHY; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; SEVERITY OF ILLNESS INDEX;

EID: 84877630186     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2011.04398.x     Document Type: Article

References (17)

1. Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, Leboit PE,. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 2000; 356: 1000-1001.
2. Jimenez SA, Artlett CM, Sandorfi N, et al. Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy): study of inflammatory cells and transforming growth factor beta1 expression in affected skin. Arthritis Rheum 2004; 50: 2660-2666.
3. Buchdunger E, Cioffi CL, Law N, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000; 295: 139-145.
4. Distler JH, Jungel A, Huber LC, et al. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum 2007; 56: 311-322.
5. Savage DG, Antman KH,. Imatinib mesylate-a new oral targeted therapy. N Engl J Med 2002; 346: 683-693.
6. Kay J, High WA,. Imatinib mesylate treatment of nephrogenic systemic fibrosis. Arthritis Rheum 2008; 58: 2543-2548.
7. Chandran S, Petersen J, Jacobs C, Fiorentino D, Doeden K, Lafayette RA,. Imatinib in the treatment of nephrogenic systemic fibrosis. Am J Kidney Dis 2009; 53: 129-132.
8. Clements P, Lachenbruch P, Siebold J, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995; 22: 1281-1285.
9. Furst DE, Clements PJ, Steen VD, et al. The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis. J Rheumatol 1998; 25: 84-88.
10. Bruce B, Fries JF,. The Health Assessment Questionnaire (HAQ). Clin Exp Rheumatol 2005; 23 (5 Suppl. 39): S14-S18.
11. Downie WW, Leatham PA, Rhind VM, Wright V, Branco JA, Anderson JA,. Studies with pain rating scales. Ann Rheum Dis 1978; 37: 378-381.
12. Bangsgaard N, Marckmann P, Rossen K, Skov L,. Nephrogenic systemic fibrosis: late skin manifestations. Arch Dermatol 2009; 145: 183-187.
13. Distler JH, Distler O,. Tyrosine kinase inhibitors for the treatment of fibrotic diseases such as systemic sclerosis: towards molecular targeted therapies. Ann Rheum Dis 2010; 69 (Suppl. 1): i48-i51.
14. Distler JH, Distler O,. Intracellular tyrosine kinases as novel targets for anti-fibrotic therapy in systemic sclerosis. Rheumatology (Oxford) 2008; 47 (Suppl. 5): v10-v11.
15. Akhmetshina A, Venalis P, Dees C, et al. Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis. Arthritis Rheum 2009; 60: 219-224.
16. Sfikakis PP, Gorgoulis VG, Katsiari CG, Evangelou K, Kostopoulos C, Black CM,. Imatinib for the treatment of refractory, diffuse systemic sclerosis. Rheumatology (Oxford) 2008; 47: 735-737.
17. van Daele PL, Dik WA, Thio HB, et al. Is imatinib mesylate a promising drug in systemic sclerosis? Arthritis Rheum 2008; 58: 2549-2552.